知镜 Cognispect · 医学文献与研究工作台

Impact of sodium-glucose cotransporter 2 (SGLT2) inhibitors on hematologic malignancy risk: Insights from Japanese claims data.

Kawashiri T, Yamamoto N, Fujiwara M, Shimizu T, Kobayashi D, Fujita S, Shibata N, Hirota T, Uchida M.
Journal of the National Cancer Institute · 2026-07-01 · PMID 41691455

文献摘要

Background Hematologic malignancies, including leukemias and lymphomas, remain life-threatening diseases for which preventive strategies have not yet been established. Recent studies have suggested that sodium-glucose cotransporter 2 (SGLT2) inhibitors have cancer-suppressive properties. This study investigated whether SGLT2 inhibitors are associated with reduced risk of hematologic malignancies in patients with diabetes, using a large-scale medical database. Methods Data of patients with diabetes prescribed diabetes medications were extracted from the JMDC Payer database (January 2005 to November 2023). After exclusions, patients were categorized into SGLT2 inhibitor (n = 158 877) and non-SGLT2 inhibitor (n = 118 678) groups. Propensity score matching, accounting for patient characteristics, resulted in 102 478 matched patients per group. The primary endpoint was time to hematologic malignancy; secondary endpoints were time to lymphoma, leukemia, and their subcategories. Results The incidence of hematologic malignancies was lower in the SGLT2 inhibitor group than in the non-SGLT2 inhibitor group (P Conclusion SGLT2 inhibitor use may be associated with lower risk of hematologic malignancies in adults with diabetes.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。